BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SUPN upcoming catalysts

Supernus Pharmaceuticals, Inc.: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 0 FDA event(s). Subscribe to SUPN (.ics).

Drugs: SPN-812, BIS-001ER, SPN-821

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Supernus Pharmaceuticals, Inc. SUPNNCT02736656 Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Attention-Deficit/Hyperactivity Disorderactive not recruiting1400
2026-12-30 est.P1/P2Supernus Pharmaceuticals, Inc. SUPNNCT03474770 BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresFocal Impaired Awareness Seizuresactive not recruiting16
2026-12-31 est.P2Supernus Pharmaceuticals, Inc. SUPNNCT07226661 Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderMajor Depressive Disorder (MDD)recruiting230

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.